A statistically significant benefit was not reached for the co-primary endpoint of recurrence-free survival in patients whose whose tumors expressed PD-L1 <1%, according to results from phase III CheckMate -915.
The phase III Takeda TOURMALINE-MM4 study met its primary endpoint of progression-free survival in multiple myeloma not treated with stem cell transplantation.
A phase II study (NCT03491683) of newly diagnosed glioblastoma multiforme combining Inovio's INO-5401 and INO-9012 in combination with Libtayo (cemiplimab) showed that 80% (16 of 20) of MGMT gene promoter methylated patients and 75% (24 of 32) of unmethylated patients were progression-free at six months measured from the time of their first dose (n = 52), substantially exceeding historical standard-of-care data.
NCI and AppliedVR have formed a collaboration to evaluate whether virtual reality can address the underlying anxiety often experienced by many patients with terminal cancer.
Thermo Fisher Scientific launched its Ion Torrent Genexus System, a fully-integrated next-generation sequencing platform featuring an automated specimen-to-report workflow that, according to the company, is able to deliver results one day.
African Americans and Hispanic people with multiple myeloma start treatment with a novel therapy significantly later than white patients, according to a study published Oct. 17 in Blood Advances.
Many non-white minority cancer survivors place importance on seeing doctors who share or understand their culture, but are less likely than non-Hispanic whites to be able to see such physicians, according to a new study from Dana-Farber Cancer Institute and University of Texas Southwestern.
The National Comprehensive Cancer Network published guidelines that provide step-by-step information on best practices in evaluating patients for hematopoietic cell transplantation and managing complications afterwards.
St. Jude Children's Research Hospital's Total Therapy Study 16 showed a reduced rate of central nervous system relapse in acute lymphoblastic leukemia, according to results published online Oct. 28 in the Journal of Clinical Oncology.
The phase III IMbrave150 study evaluating Tecentriq in combination with Avastin in people with unresectable hepatocellular carcinoma met its co-primary endpoints of overall survival and progression-free survival, compared with standard-of-care sorafenib.
